Literature DB >> 7782288

Multiple transcripts for the human cardiac form of the cGMP-inhibited cAMP phosphodiesterase.

J Kasuya1, H Goko, Y Fujita-Yamaguchi.   

Abstract

cDNAs for two distinct Type III cGMP-inhibited (cGI) cyclic nucleotide phosphodiesterases (PDE), designated cGIP1 and cGIP2, were previously cloned from rat adipose and human cardiac cDNA libraries, respectively. In this study, another cDNA (approximately 4.0 kilobase (kb)) encoding a cGI-PDE of 74 kDa (658 amino acids) was isolated from a human placental cDNA library. The nucleotide sequence of its open reading frame was virtually identical to a corresponding region in the 3' portion of the cardiac cGIP2 cDNA (approximately 7.6 kb) which encoded a approximately 125-kDa cGI-PDE (1141 amino acid). Northern blots and RNase protection assays revealed a prominent 4.4-kb transcript and a 7.6-kb transcript in human placenta. The transcription start site of the 4.4-kb transcript was assigned to cardiac cDNA nucleotide 1292, the putative beginning of exon 3 of the human cGIP2 gene, with a potential translation initiation site 183 bases downstream, as determined by RNase protection assay. The 5'-flanking region of the 4.4-kb transcript exhibited promoter activity in HeLa cells which expressed the 4.4-kb transcript, and contained a TATAA sequence 35 base pairs upstream from the tentative transcription start site. Recombinant cGI-PDEs, expressed in Sf9 cells from the 7.6- and 4.0-kb cDNA, exhibited differences in their subcellular localization and Km for cGMP. Thus, in human tissues, alternative transcription may contribute to generating at least two cGIP2 isoforms, cytosolic and membrane-associated cGI-PDEs with different Km values for cGMP.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7782288     DOI: 10.1074/jbc.270.24.14305

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Identification of a novel isoform of the cyclic-nucleotide phosphodiesterase PDE3A expressed in vascular smooth-muscle myocytes.

Authors:  Y H Choi; D Ekholm; J Krall; F Ahmad; E Degerman; V C Manganiello; M A Movsesian
Journal:  Biochem J       Date:  2001-01-01       Impact factor: 3.857

2.  Phosphodiesterase 3 inhibitors suppress oocyte maturation and consequent pregnancy without affecting ovulation and cyclicity in rodents.

Authors:  A Wiersma; B Hirsch; A Tsafriri; R G Hanssen; M Van de Kant; H J Kloosterboer; M Conti; A J Hsueh
Journal:  J Clin Invest       Date:  1998-08-01       Impact factor: 14.808

3.  Expression and mutagenesis of the catalytic domain of cGMP-inhibited phosphodiesterase (PDE3) cloned from human platelets.

Authors:  K M Tang; E K Jang; R J Haslam
Journal:  Biochem J       Date:  1997-04-01       Impact factor: 3.857

4.  High cGMP and low PDE3A activity are associated with oocyte meiotic incompetence.

Authors:  Eran Gershon; Iris Maimon; Dalia Galiani; Michal Elbaz; Sharon Karasenti; Nava Dekel
Journal:  Cell Cycle       Date:  2019-08-12       Impact factor: 4.534

5.  Insulin receptor substrate 1 binds two novel splice variants of the regulatory subunit of phosphatidylinositol 3-kinase in muscle and brain.

Authors:  D A Antonetti; P Algenstaedt; C R Kahn
Journal:  Mol Cell Biol       Date:  1996-05       Impact factor: 4.272

Review 6.  Targeting phosphodiesterases in anti-platelet therapy.

Authors:  Matthew T Rondina; Andrew S Weyrich
Journal:  Handb Exp Pharmacol       Date:  2012

7.  Identification of cytosolic phosphodiesterases in the erythrocyte: a possible role for PDE5.

Authors:  Shaquria P Adderley; Kelly M Thuet; Meera Sridharan; Elizabeth A Bowles; Alan H Stephenson; Mary L Ellsworth; Randy S Sprague
Journal:  Med Sci Monit       Date:  2011-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.